221 related articles for article (PubMed ID: 28778166)
1. Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.
Carmichael JD; Broder MS; Cherepanov D; Chang E; Mamelak A; Said Q; Neary MP; Bonert V
BMC Endocr Disord; 2017 Aug; 17(1):49. PubMed ID: 28778166
[TBL] [Abstract][Full Text] [Related]
2. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway.
Falch CM; Dupont AK; Olarescu NC; Wiedmann M; Dahlberg D; Bollerslev J; Berg-Johnsen J; Heck A
Acta Neurochir (Wien); 2023 Oct; 165(10):3003-3010. PubMed ID: 37665404
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
4. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
5. Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time.
Ghajar A; Jones PS; Guarda FJ; Faje A; Tritos NA; Miller KK; Swearingen B; Nachtigall LB
J Clin Endocrinol Metab; 2020 Mar; 105(3):e532-43. PubMed ID: 31701145
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register.
Arnardóttir S; Järås J; Burman P; Berinder K; Dahlqvist P; Erfurth EM; Höybye C; Larsson K; Ragnarsson O; Ekman B; Edén Engström B
Eur J Endocrinol; 2022 Feb; 186(3):329-339. PubMed ID: 35007208
[TBL] [Abstract][Full Text] [Related]
7. Therapy for the syndromes of GH excess.
Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
[TBL] [Abstract][Full Text] [Related]
8. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
9. Acromegaly: presentation, morbidity and treatment outcomes at a single centre.
Anagnostis P; Efstathiadou ZA; Polyzos SA; Adamidou F; Slavakis A; Sapranidis M; Litsas ID; Katergari S; Selalmatzidou D; Kita M
Int J Clin Pract; 2011 Aug; 65(8):896-902. PubMed ID: 21679284
[TBL] [Abstract][Full Text] [Related]
10. Cost of management of invasive growth hormone-secreting macroadenoma.
Luque-Ramírez M; Paramo C; Varela da Costa C; García-Mayor RV
J Endocrinol Invest; 2007; 30(7):541-5. PubMed ID: 17848835
[TBL] [Abstract][Full Text] [Related]
11. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period.
Karapanou O; Tzanela M; Christoforaki M; Papastathopoulou L; Moutsatsou P; Botoula E; Tsagarakis S
Hormones (Athens); 2016 Jul; 15(3):368-376. PubMed ID: 27394702
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
[TBL] [Abstract][Full Text] [Related]
14. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
15. The association between biochemical control and cardiovascular risk factors in acromegaly.
Carmichael JD; Broder MS; Cherepanov D; Chang E; Mamelak A; Said Q; Neary MP; Bonert V
BMC Endocr Disord; 2017 Mar; 17(1):15. PubMed ID: 28279153
[TBL] [Abstract][Full Text] [Related]
16. Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.
Evran M; Sert M; Tetiker T
BMC Endocr Disord; 2014 Dec; 14():97. PubMed ID: 25511633
[TBL] [Abstract][Full Text] [Related]
17. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
[TBL] [Abstract][Full Text] [Related]
18. Acromegaly.
Chanson P; Salenave S; Kamenicky P
Handb Clin Neurol; 2014; 124():197-219. PubMed ID: 25248589
[TBL] [Abstract][Full Text] [Related]
19. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY.
Shanik MH
Endocr Pract; 2016 Feb; 22(2):210-9. PubMed ID: 26437214
[TBL] [Abstract][Full Text] [Related]
20. The role of endogenous growth hormone-releasing hormone in acromegaly.
Dimaraki EV; Chandler WF; Brown MB; Jaffe CA; Kim SY; Taussig R; Padmanabhan V; Barkan AL
J Clin Endocrinol Metab; 2006 Jun; 91(6):2185-90. PubMed ID: 16537684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
